In patients with acute myeloid leukemia and myelodysplastic syndrome, treatment with sabatolimab administered at 200 mg every 2 weeks and 800 mg every 4 weeks demonstrated similar pharmacokinetic activity, according to findings from a dose-selection and dose-response analysis presented during the 2020 American Society of Hematology Annual Meeting.
An overall response rate of 53% was observed with the first-of-its-kind FcRH5xCD3 bispecific antibody cevostamab along with manageable safety as treatment of patients with heavily pretreated patients with relapsed/refractory multiple myeloma who received active doses, according to results from a phase 1 dose-escalation study.
Encouraging response rates were observed in patients with relapsed or refractory multiple myeloma who were treated with off-the-shelf DuoBody IgG4 PAA binding antibody talquetamab. In addition, the agent showed a tolerable safety profile, according to early data from a phase 1 clinical trial.
Patients with relapsed or refractory multiple myeloma had deep and durable responses to the BCMA- and CD3-targeted bispecific monoclonal antibody REGN5458, early on in the course of treatment, according to findings from a first-in-human phase 1 study.
In patients with relapsed or refractory lymphoma, treatment with the investigational CD47-blocker TTI-622 appeared well tolerated and demonstrated preliminary activity, according to results from a phase 1a clinical trial presented in a poster during the 2020 American Society of Hematology Virtual Annual Meeting.
A real-world analysis showed the positive safety and efficacy of the investigational tyrosine kinase inhibitor asciminib as treatment of patients with chronic myeloid leukemia without any alternatives in clinical practice.
A research collaboration has identified that patients with hematologic malignancies who are infected with coronavirus disease 2019 are at greater risk for poor outcomes from the virus.
Early signs of clinical activity were observed in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia who were treated with an investigational allogeneic off-the-shelf CD22-directed therapy.
Naveen Pemmaraju, MD, discusses the next steps for research in the field of myelofibrosis.
In a post hoc analysis of the DREAMM-2 trial, belantamab mafodotin achieved deep and durable responses with no notable alterations in its safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma who had received ≥7 prior therapies.
A novel BCMA and CD3 targeted bispecific T-cell engaging immunotherapy agent TNB-383B has demonstrated significant responses at higher dose levels and tolerability at all dose levels, including mild cases of cytokine release syndrome, according to initial results of a phase 1 trial presented during the 2020 American Society of Hematology Annual Meeting.
Allogeneic hematopoietic stem cell transplant with a donor leads to significant improvements in outcomes, even for patients up to age 75, in patients with higher-risk myelodysplastic syndrome.
Treatment with a novel tri-specific natural killer cell engager agent led to natural killer cell proliferation across dose levels in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.
The ongoing phase 1/2 DREAMM-6 trial demonstrated clinical activity and a good safety profile with the combination of belantamab mafodotin, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.
Ciltacabtagene autoleucel demonstrated a significant response rate and showed a manageable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.
The addition of the oral selective RARα agonist SY-1425 to azacitidine induced clinical activity as treatment of patients with heavily pretreated relapsed/refractory acute myeloid leukemia with RARA positivity.
Enriching the CAR molecule bb2121 with the PI3K inhibitor bb007 improved response and extended duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.
Treatment with axicabtagene ciloleucel resulted in high rates of durable responses in patients with indolent non-Hodgkin lymphoma.
Updated findings from the phase 1 CRB-401 trial of the chimeric antigen receptor T-cell therapy idecabtagene vicleucel showed a consistently favorable risk profile as well as durable, ongoing responses in heavily pretreated patients with multiple myeloma.
Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.
Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Treatment with selinexor, bortezomib, and dexamethasone demonstrated an increase in overall response rate and progression-free survival in patients with multiple myeloma and high cytogenetic risk despite a dosing schedule that utilized 40% less bortezomib and 25% less dexamethasone during the first 24 weeks of treatment.
Patients with refractory large B-cell lymphoma experienced long-term disease control with rapid responses and robust CAR T-cell expansion with the CAR T-cell therapy axicabtagene ciloleucel.
Patients with intermediate- or high-risk myelofibrosis in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials experienced improved overall survival and sustained efficacy outcomes with momelitinib.
In a phase 1 study of patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, the anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 demonstrated activity, durable responses, safety, and tolerability.
Higher doses of telomerase inhibitor imetelstat demonstrated better overall survival, spleen response, and symptom response in patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors in the phase 2 IMbark study.
Significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia in the Chicago metropolitan area were seen with census tract socioeconomic status information.
A post-hoc analysis of the SADAL trial showed there was clinical benefit with selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma regardless of age.
Patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy had significantly prolonged overall survival and relapse-free survival with azacitidine.
The oral, selective menin inhibtor KO-539 showed activity in preliminary findings of the ongoing first-in-human KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia.